Department of Basic Medical Sciences, 108598Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
37559King Hussein Cancer Center, Amman, Jordan.
Int J Biol Markers. 2022 Sep;37(3):322-327. doi: 10.1177/03936155221104122. Epub 2022 May 29.
Few studies have addressed the clinicopathological features of colorectal cancer (CRC) that express programed death-ligand 1 (PD-L1). Various assays and scoring methodologies were used and thus inconsistent results were obtained. In this study, we aimed to investigate the relationship of PD-L1 expression in CRC with various clinicopathological variables using a standardized assay and scoring algorithm.
Tissue microarrays were constructed from 91 random cases of CRC diagnosed at King Hussein Cancer Center (KHCC). Immunohistochemical (IHC) staining using the monoclonal antibody 22C3 was performed. Scoring using the standard "Combined Positive Score" (CPS) method was done. CPS of ≥1 was considered positive. Various clinicopathological features were collected from the medical records of the patients.
Of the 91 cases, 49 (53.8%) were PD-L1 positive (CPS ≥1). PD-L1 expression was more frequent among moderately differentiated carcinomas (43 of 72 (59.7%) were positive compared to 6 of 19 (31.5%) poorly differentiated cases ( = 0.029)); among node negative cases (21 of 24 (87.5%) N0 cases were PD-L1 positive in contrast to 28 of 67 (41.8%) N1/N2 cases ( = <0.001)); among mucinous subtype (12 of 15 (80%) of cases ( = 0.02)); and among mismatch repair deficient (dMMR) (16 of 16 (100%) versus 11 of 30 (36.6%) MMR proficient ( = <0.001)). Age, gender, localization, and T or M stages were not significantly associated with PD-L1 expression.
PD-L1 expression in CRC is associated with favorable prognostic features; namely, lower grade, N0, mucinous variant, and dMMR tumors.
鲜有研究探讨表达程序性死亡配体 1（PD-L1）的结直肠癌（CRC）的临床病理特征。不同的检测方法和评分方法被应用，导致结果不一致。本研究旨在使用标准化检测方法和评分算法，探讨CRC 中 PD-L1 表达与各种临床病理变量的关系。
从侯赛因国王癌症中心（KHCC）诊断的 91 例随机 CRC 病例中构建组织微阵列。使用单克隆抗体 22C3 进行免疫组织化学（IHC）染色。采用标准的“综合阳性评分”（CPS）方法进行评分。CPS≥1 被认为是阳性。从患者的病历中收集了各种临床病理特征。
在 91 例病例中，49 例（53.8%）PD-L1 阳性（CPS≥1）。中分化癌中 PD-L1 表达更为常见（43/72 例（59.7%）阳性，而 19/19 例（31.5%）低分化癌中阳性）（ = 0.029）；淋巴结阴性病例中（24/24 例（87.5%）N0 病例 PD-L1 阳性，而 67/67 例（41.8%）N1/N2 病例中阳性）（ = <0.001）；黏液亚型中（15/15 例（80%）病例阳性）（ = 0.02）；错配修复缺陷（dMMR）中（16/16 例（100%）阳性，而 30/30 例（36.6%）错配修复完整（MMR）阳性）（ = <0.001）。年龄、性别、定位和 T 或 M 分期与 PD-L1 表达无显著相关性。
CRC 中 PD-L1 表达与有利的预后特征相关；即低级别、N0、黏液型和 dMMR 肿瘤。
